Skip to main content

Crucial involvement of xanthine oxidoreductase in the biological responses of myeloid hematopoietic cells

Abooali, Maryam (2015) Crucial involvement of xanthine oxidoreductase in the biological responses of myeloid hematopoietic cells. Doctor of Philosophy (PhD) thesis, University of Kent. (doi:10.22024/UniKent/01.02.49841) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:49841)

Language: English

Restricted to Repository staff only
[thumbnail of Crucial involvement of xanthine_thesis.pdf]
Official URL:


Xanthine oxidoreductase (XOR) is one of the main purine catabolising enzymes which converts hypoxanthine into xanthine and further into uric acid. The enzyme has a homodimeric structure and contains two FeS centres, one FAD molecule and one molybdenum atom per monomer. Recent evidence clearly demonstrated that XOR activity is highly increased in human hematopoietic cells of myeloid lineage during their pathogen-induced and endogenously generated biological responses. The integrative signalling role and especially involvement of XOR in cross-talk of metabolic and signalling machinery of human leukocytes remains poorly understood.

We have demonstrated that XOD is activated in human myeloid cells in response to pro-inflammatory and growth factor stimulation. Hypoxia-inducible factor 1 (HIF-1) and activator protein 1 (AP1) transcription complexes were found responsible for maintaining XOR catalytic activity and protein levels. Importantly, the mammalian target of rapamycin (mTOR), a major myeloid cell translation regulator, appeared to be essential for XOR activation. Specific inhibition of XOR led to an increase in intracellular AMP levels triggering downregulation of mTOR activation. Taken together, these results show that XOD is not only activated by pro-inflammatory stimuli or SCF (growth factors), but also plays a crucial role in maintaining mTOR-dependent translational control during the biological responses of hematopoietic cells of myeloid lineage.

Findings reported in this thesis open a new field in human myeloid cell research and translational medicine. XOR is an easily accessible therapeutic target, which could be pharmacologically corrected using non-toxic drugs.

Item Type: Thesis (Doctor of Philosophy (PhD))
Thesis advisor: Sumbayev, Vadim
Thesis advisor: Gibbs, Bernhard
DOI/Identification number: 10.22024/UniKent/01.02.49841
Additional information: The author of this thesis has requested that it be held under closed access. We are sorry but we will not be able to give you access or pass on any requests for access. 25/05/22
Uncontrolled keywords: AP-1 – Activating Protein-1 HIF-1 – Hypoxia-Inducible Factor 1 mTOR – Mammalian target of rapamycin XOR – Xanthine oxidoreductase
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User: Users 1 not found.
Date Deposited: 27 Jul 2015 11:00 UTC
Last Modified: 28 Jul 2022 08:53 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

Abooali, Maryam.

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.